Uses of monoclonal antibody 8H9

Details Uses of monoclonal antibody 8H9 Uses of monoclonal antibody 8H9

2002-03-08

2010-06-15

Yu, Misook (Department: 1642)

Chemistry: natural resins or derivatives; peptides or proteins;

Proteins, i.e., more than 100 amino acid residues

Blood proteins or globulins, e.g., proteoglycans, platelet...

Reexamination Certificate

active

07737258

ABSTRACT:
This invention provides a composition comprising an effective amount of monoclonal antibody 8H9 or a derivative thereof and a suitable carrier. This invention provides a pharmaceutical composition comprising an effective amount of monoclonal antibody 8H9 or a derivative thereof and a pharmaceutically acceptable carrier. This invention also provides an antibody other than the monoclonal antibody 8H9 comprising the complementary determining regions of monoclonal antibody 8H9 or a derivative thereof, capable of binding to the same antigen as the monoclonal antibody 8H9. This invention provides a substance capable of competitively inhibiting the binding of monoclonal antibody 8H9. This invention also provides an isolated scFv of monoclonal antibody 8H9 or a derivative thereof. This invention also provides the 8H9 antigen. This invention also provides a method of inhibiting the growth of tumor cells comprising contacting said tumor cells with an appropriate amount of monoclonal antibody 8H9 or a derivative thereof.

REFERENCES:
patent: 5270202 (1993-12-01), Raychaudhuri
patent: 5693762 (1997-12-01), Queen et al.
patent: 6132718 (2000-10-01), Hansen
patent: 6326471 (2001-12-01), Kokolus et al.
patent: 6632431 (2003-10-01), Wu
patent: 2002/0102264 (2002-08-01), Cheung
patent: 2002/0132983 (2002-09-01), Junghans
patent: 2003/0103963 (2003-06-01), Cheung
patent: 2003/0149998 (2003-08-01), Blatcher et al.
patent: WO 03/075846 (2003-09-01), None
patent: WO 2004/050849 (2004-06-01), None
Queen et al., (PNAS, 1999, vol. 86, pp. 10029-10033).
International Search Report Apr. 2, 2002 International Search Report from Patent Cooperation Treaty for International Patent Application Uses of Monoclonal Antibody 8H9 for Sloan-Kettering Institute for Cancer Research, et al. International application No. PCT/US01/32565, International Filing Date Oct. 18, 2001, claiming benefit of U.S. Appl. No. 60/241,344, filed Oct. 28, 2000, and U.S. Appl. No. 60/330,396, filed Oct. 17, 2001. (Exhibit 1).
Juhl, et al. Additive Cytotoxicity of Different Monoclonal Antibody-Cobra Venom Factor Conjugates for Human Neuroblastoma Cells, Immunobiology, Nov. 1997, vol. 197, pp. 444-459 (Exhibit 2).
Modak, et al. Radioimmunotargeting to Human Rhabdomyosarcoma (RMS) using Monoclonal Antibody (MOAB) 8H9, Proceedings of the American Association for Cancer Research Annual Meeting, Mar. 2000 .vol. 41 pp. 724, Abstract 4600. (Exhibit 3).
Xu, et al. Targeting and therapy of carcinoembryonic antigen-expressing tumors in transgenic mice with an antibody-interleukin 2 fusion protein, Cancer Res Aug. 15, 2000, vol. 60, No. 16, pp. 4475-4484, abstract only. (Exhibit 4).
Pegram, M. D. Salmon, D. J., Combination therapy with trastuzumab (Herceptin) and cisplatin for chemoresistant metastatic breast cancer: evidence for receptor-enhanced chemosensitivity. Sem. Oncol., 26:89-95, 1999. (Exhibit 5).
Bigner, D. D. et al Iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas:phase I trial results. Journal Clinical Oncology, 16:2202-2212, 1998. (Exhibit 6).
Bruland, O. et al. New monoclonal antibodies specific for human sarcomas. Int J Cancer, 15:27-31, 1986. (Exhibit 7).
Wang, N. P. et al. Expression of myogenic regulatory proteins (myogenin and MyoD1) in small blue round cell tumors of childhood. Am. J. Pathol., 147:1799-1810, 1995. (Exhibit 8).
Bigner, D. D. et al. Phase I studies of treatment of malignant gliomas and neoplastic meningitis with 131 I radiolabeled monoclonal antibodies anti-tenascin 81C6 and anti-chondroitin proteoglycan sulfate Mel-14 (ab′) 2—a preliminary report. J Neuro Oncol, 24:109-122, 1995. (Exhibit 9).
Mariani, G. et al. A pilot pharmacokinetic and immunoscintigraphic study with the technetium-99m-labeled monoclonal antibody BC-1 directed against oncofetal fibronectin in patients with brain tumors. Cancer Supplement, 80:2484-2489, 1997. (Exhibit 10).
DiMaggio JJ et al. Monoclonal antibody therapy of cancer. In: Pinedo HM, Chabner BA, Longo DL, (eds.) : Cancer Chemotherapy and Biological Response Modifiers, Annual 11, Elsevier Science Publishers B.V., (Biomedical Division), 1990, pp. 177-203 (Exhibit 11).
Schlom J. Monoclonal Antibodies in cancer therapy: Basic principles. In : DeVita VT, Hellman S, Rosenberg SA, (eds.) : Biologic therapy of cancer, 2nd ed. Philadelphia, J.B.Lippincott Co, 1995, pp. 507-520 (Exhibit 12).
Lode HN. et al. Immunocytokines: A promising approach to cancer immunotherapy. Pharmacology Therapeutics 80:277-292, 1998 (Exhibit 13).
Erikson HP. et al. Hexabrachion protein (tenascin, cytotactin, brachionectin) in connective tissues, embryonic tissues and tumors. Adv Cell Biol 2:55-90, 1988 (Exhibit 14).
Modak S. et al. Novel tumor-associated surface antigen: broad distribution among neuroectodermal, mesenchymal and epithelial tumors, with restricted distribution in normal tissues. Proceedings of ASCO 17:449a, 1998, Abstract 1716 (Exhibit 15).
Cheung NK. et al. Treatment of advanced stage neuroblastoma. In: Reghavan D, Scher HI, Leibel SA, Lange P, (eds.) : Principles and Practice of Genitourinary Oncology. Philadelphia, J.B. Lippincott Company, 1997, pp. 1101-1111 (Exhibit 16).
Brodeur G.M. et al. Neuroblastoma. In: Pizzo PA, Poplack DG, (eds.) : Principles and Practice of Pediatric Oncology, 3rd ed. Philadelphia, J.B. Lippincott Company, 1997, pp. 761-797 chapter 2 (Exhibit 17).
Cheung N.K.V. et al. Biological and molecular approaches to diagnosis and treatment. section I. Principles of Immunotherapy. In: Pizzo PA, Poplack, DG, (eds.) : Principles and Practice of Pediatric Oncology, 3rd ed. ed. Philadelphia, J.B. Lippincott Company, 1997, pp. 323-342 (Exhibit 18).
Larson S.M. et al. Antibodies in cancer therapy: Radioisotope conjugates. In: DeVita VT, Hellman S, Rosenberg SA, (eds.) Biologic Therapy of Cancer, 2nd ed. Philadelphia, J.B. Lippincott Co., 1995, pp. 534-552 (Exhibit 19).
Reisfeld R.A. et al. Potential of genetically engineered anti-ganglioside GD2 antibodies for cancer immunotherapy. In: Progress in Brain Search (Svennerhol,L, Asbury,AK, Reisfeld,RA, Sandhoff,K, Suzuki,K, Tettamani,G, Toffano,G, vol. 101. Cambridge, UK, Elsevier Trends Journals, 1994, pp. 201-212 (Exhibit 20).
Cheung N.K.V. et al. Decay-accelerating factor protects human tumor cells from complement-mediated cytotoxicity in vitro. J Clin Invest 81:1122-1128, 1988 (Exhibit 21).
Murray J.L. et al. Phase I trial of murine monoclonal antibody 14G2a administered by prolonged intravenouos infusion in patients with neuroectodermal tumors. J Biol Resp Modif 1991 (Soc. Biol. Therapy Meeting Abstract 1991.) Journal of Clinical Oncology, vol. 12, No. 1 (January), 1994; pp. 184-193 (Exhibit 22).
Ugur O. et al. Comparison of the targeting characteristics of various radioimmunoconjugates for radioimmunotherapy of neuroblastoma: Dosimetry calculations incorporating cross-organ beta doses. Nucl Med Biol 23:1-8, 1996 (Exhibit 23).
Saleh M.N. et al. Phase I trial of the murine monoclonal anti-GD2 antibody 14G2a in metastatic melanoma. Cancer Research 52, 4342-4347, Aug. 15, 1992 (Exhibit 24).
Handgretinger R. et al. A phase I study of human/mouse chimeric antiganglioside GD2 antibody ch14.18 in patients with neuroblastoma. Eur J Cancer 31:261-267, 1995 (Exhibit 25).
Cheung N.K.V. et al. 3F8 monoclonal antibody treatment of patients with stage IV neuroblastoma: a phase II study. In: Evans AE, Guillio JD, Biedler JL, et al, (eds.) : Advances in Neuroblastoma Research, vol. 4. New York, Wiley Liss, 1994, pp. 319-329 (Exhibit 26).
Yu A.L. et al. Phase I clinical trial of ch14.18 in patients with refractory neuroblastoma. Proc Am Soc Clin Oncol 10:318, 1991, Abstract 1118 (Exhibit 27).
Cheung N.K. Biological and Molecular Approaches to Diagnosis and Treatment. Immunotherapy. In: Pizzo PA, Poplack DG, (eds.) : Principles and Practice of Pediatric Oncology, 2nd ed. Philadelphia, J.B.Lippincott Company, 1992, pp. 357-370 (Exhibit 28).
Cheung N.K.V. et al. 3F8 monoclonal antibody treatment of patients with stage IV neuroblastoma: A phase II Study. Int J Oncol 12:1299-1306, 1

Affiliated with

Also associated with

Rating

Uses of monoclonal antibody 8H9 does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Uses of monoclonal antibody 8H9, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Uses of monoclonal antibody 8H9 will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4211868